James William Rogers Sells 26,313 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 26,313 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total value of $1,578,780.00. Following the sale, the chief financial officer owned 106,024 shares of the company’s stock, valued at approximately $6,361,440. This represents a 19.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

James William Rogers also recently made the following trade(s):

• On Tuesday, August 18th, James William Rogers sold 22,529 shares of Tempus AI stock. The stock was sold at an average price of $49.61, for a total value of $1,117,663.69.
• On Thursday, June 25th, James William Rogers sold 11,529 shares of Tempus AI stock. The stock was sold at an average price of $55.00, for a total value of $634,095.00.

Tempus AI Trading Up 9.1%

Shares of NASDAQ:TEM opened at $72.69 on Friday. The business’s 50-day moving average is $52.93 and its 200 day moving average is $51.36. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $104.32. The firm has a market capitalization of $13.12 billion, a P/E ratio of -50.48 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm’s revenue was up 21.6% compared to the same quarter last year. During the same period last year, the business posted ($0.22) earnings per share. On average, research analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Tempus AI

A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Tempus AI by 8.7% in the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock valued at $605,772,000 after buying an additional 817,014 shares in the last quarter. ARK Investment Management LLC raised its position in shares of Tempus AI by 5.3% in the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after acquiring an additional 381,816 shares during the period. GC Wealth Management RIA LLC purchased a new stake in shares of Tempus AI during the 4th quarter worth about $399,267,000. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after acquiring an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. grew its position in shares of Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after acquiring an additional 821,490 shares during the period. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target for Tempus AI to $80 from $70 and maintained a “Buy” rating. The higher target strengthens the bullish case and provides a near-term catalyst for the stock. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is building around Tempus AI’s planned approximately $1.5 billion all-stock acquisition of Personalis. The deal could expand Tempus’ genomic-data, cancer-testing and drug-development capabilities, potentially increasing its strategic value in precision medicine. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Merck and Moderna’s cancer-vaccine trial developments have heightened interest in oncology data and genomic testing. The connection to Tempus is indirect, but the news reinforces the company’s cancer-data and personalized-treatment growth narrative. Tempus AI stock move and Merck-Moderna trial news
• Positive Sentiment: Trading activity in TEM call options was unusually high, with reported volume roughly 57% above normal. This indicates bullish speculation and may be amplifying the stock’s momentum, though options activity can also increase volatility.
• Neutral Sentiment: The stock has moved above its 50-day and 200-day moving averages, raising the possibility of momentum buying or a short squeeze. That technical strength could support further gains, but it also increases the risk of a sharp reversal.
• Negative Sentiment: Tempus AI’s CEO, CFO, EVP and chief accounting officer sold shares, with the largest reported transaction involving CEO Eric Lefkofsky. The sales reduced executives’ holdings and may concern investors, but they were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

Analyst Ratings Changes

A number of research firms recently commented on TEM. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. HC Wainwright cut their price target on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. Lake Street Capital cut shares of Tempus AI to a “hold” rating in a report on Monday, July 20th. TD Cowen reiterated a “buy” rating on shares of Tempus AI in a research note on Wednesday, July 15th. Finally, Piper Sandler cut their target price on Tempus AI from $58.00 to $56.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Tempus AI has an average rating of “Hold” and a consensus target price of $65.69.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.